PD
MDGL icon

Point72 (DIFC)’s Madrigal Pharmaceuticals MDGL Stock Holding History

Point72 (DIFC)’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$75.3K Buy
164
+160
+4,000% +$59.7K ﹤0.01% 645
2025
Q2 		$1.13K Buy
+4
New +$1.19K ﹤0.01% 1433

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Point72 (DIFC)'s MDGL Position: Q3 2025 in Review

Point72 (DIFC) increased its Madrigal Pharmaceuticals (MDGL) stake by 4,000% in Q3 2025, buying an estimated $59.7K and bringing the position to 164 shares worth $75.3K. The position accounts for ﹤0.01% of the portfolio, ranked #645.

Point72 (DIFC) first reported a position in MDGL in Q2 2025 and has held it in 2 quarters since. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Point72 (DIFC) held 164 shares of Madrigal Pharmaceuticals worth $75.3K as of Q3 2025.
  • Point72 (DIFC) bought 160 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $59.7K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #645 holding.
  • Point72 (DIFC) first reported a position in Madrigal Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.